AC
NBIX icon

AlphaCore Capital’s Neurocrine Biosciences NBIX Stock Holding History

AlphaCore Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$349K Buy
+2,649
New +$351K 0.01% 651

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AlphaCore Capital's NBIX Position: Q1 2026 in Review

AlphaCore Capital opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 2,649 shares worth $349K. The stake represents 0.01% of the portfolio and ranks #651 among its holdings.

694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • AlphaCore Capital held 2,649 shares of Neurocrine Biosciences worth $349K as of Q1 2026.
  • Neurocrine Biosciences was a new AlphaCore Capital position in Q1 2026.
  • Neurocrine Biosciences made up 0.01% of AlphaCore Capital's portfolio in Q1 2026, its #651 holding.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.